

Application No. 10/084,813

Reply to Office Action

ALLOWED  
CLAIMS  
JW  
02/06/07

**AMENDMENTS TO THE CLAIMS**

This listing of claims replaces all prior versions, and listings, of claims in the application.

21, 60, 70 - 85 (1-19)

1.-20. (Canceled)

1 21. (Currently Amended) A polypeptide comprising an amino acid sequence selected from the group consisting of QWDFGNTMCQLLTGLYFIGFFS (SEQ ID NO: 12), SQYQFWKNFQTLKIVILG (SEQ ID NO: 13), APYNIVLLLNTFQE<sup>18</sup>FFGLNNCS (SEQ ID NO: 14), YAFVGEKFRNYLLVFFQK (SEQ ID NO: 15), and SEQ ID NOs: 12-15 with up to ~~some~~ conservative or neutral amino acid substitutions substitution, wherein the polypeptide binds with HIV gp120 under physiological conditions and comprises less than 100 contiguous amino acid residues that are identical to the amino acid sequence of the human CCR5 chemokine receptor.

22.-59. (Canceled)

2 60. (Previously Presented) A composition comprising the polypeptide of claim 21 and a carrier.

61.-69. (Canceled)

3 70. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises QWDFGNTMCQLLTGLYFIGFFS (SEQ ID NO: 12).

4 71. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises SQYQFWKNFQTLKIVILG (SEQ ID NO: 13).

5 72. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises APYNIVLLLNTFQE<sup>18</sup>FFGLNNCS (SEQ ID NO: 14).

6 73. (Previously Presented) The polypeptide of claim 21, wherein the polypeptide comprises YAFVGEKFRNYLLVFFQK (SEQ ID NO: 15).

Application No. 10/084,813

Reply to Office Action

7 (74) (Currently Amended) The polypeptide of claim 21, wherein the polypeptide comprises QWDFGNTMCQLLTGLYFIGFFS (SEQ ID NO: 12) with up to ~~8~~ one conservative or neutral amino acid substitutions substitution.

8 (75) (Currently Amended) The polypeptide of claim 21, wherein the polypeptide comprises SQYQFWKKNFQTLKIVILG (SEQ ID NO: 13) with up to ~~8~~ one conservative or neutral amino acid substitutions substitution.

9 (76) (Currently Amended) The polypeptide of claim 21, wherein the polypeptide comprises APYNIVLLLNTFQEFFFGLNNCS (SEQ ID NO: 14) with up to ~~8~~ one conservative or neutral amino acid substitutions substitution.

10 (77) (Currently Amended) The polypeptide of claim 21, wherein the polypeptide comprises YAFVGEKFRNYLLVFFQK (SEQ ID NO: 15) with up to ~~8~~ one conservative or neutral amino acid substitutions substitution.

11 (78) (Previously Presented) A composition comprising the polypeptide of claim 70 and a carrier.

12 (79) (Previously Presented) A composition comprising the polypeptide of claim 71 and a carrier.

13 (80) (Previously Presented) A composition comprising the polypeptide of claim 72 and a carrier.

14 (81) (Previously Presented) A composition comprising the polypeptide of claim 73 and a carrier.

15 (82) (Previously Presented) A composition comprising the polypeptide of claim 74 and a carrier.

16 (83) (Previously Presented) A composition comprising the polypeptide of claim 75 and a carrier.

17 (84) (Previously Presented) A composition comprising the polypeptide of claim 76 and a carrier.

Application No. 10/084,813

Reply to Office Action

18 (85) (Previously Presented) A composition comprising the polypeptide of claim 77 and a carrier.

86.-89. (Canceled)